Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Alright —.30 @3 million plus volume
I million volume in hour 1
Yeah baby. 2 million traded. Let’s see 4 million by end of week.
Yes please. Leo…….let’s go!
I do! Great value here in anti viral land
Pre result run! We’ve seen this movie before ;). Up 30 cents and hopefully this time we get “no doubt about it” crystal clear Covid changing results!!!! To infinity and beyond!
I do not want this Covid to resurge! But the timing could not be more perfect for iPix shareholders and data release. IMO
I’m not a doctor but here is my theory. No science just my theory.
I believe these vaccines are a very bad idea. Since the rollout is so slow globally there is ample room for mutations and I believe these vaccines are going to cause an even worse and more ungodly mutation.
This virus is like a wild fire
We are the brush and trees
Unvaccinated folks are dried up trees
Vaccinated people are more like plastic trees. How does plastic burn?
I read some experts believe the virus is still being transmitted at a very high level and thru vaccinated people. The reason the reports are so low is because yes…vaccinated folks have the virus for a shorter period and less severe. So no one is getting tested. Also there are at home tests now that are not reported.
In 2 years we may see a virus that is uncontrollable due to mutations and take out the entire population because of this vaccine. Viruses need a host and will figure out how to survive.
Just a feeling I have. Sweet dreams.
Come on brilacidin. The silver bullet that punctures all viruses…and does not discriminate or feed mutation.
Up 8 million shares since the past 2 Q’s
Dunn. The company already have the drug in a phase 3. Plus the Co is responsible for everything to move the drug to approval. Much different terms.
Leo had B in basically a phase 1 reformulation for UPS a smaller indication. Alpha has all responsibility to reformulate and run and pay for all trials. Leo and iPix just sit back and relax. And collect milestones if it works. All while the data and progress is Leo’s to share to other possible partners as Alpha helps solidify and anchor Bs magical powers
Welcome a board! There are always the chances of failure compared to in vitro.
We are only several weeks away from finding out. If we see great data this share price will explode. It’s been held down on dilution for many years. Time to get a quick few hundred million in the bank. Then Leo will have the muscle to go where he told us
Low volume and let’s see zero additional OS for two quarters in a row!
Heavy investment is paying for the reformulation, the trial, the drug….etc! We all know that is not cheap and they could have stopped after phase 1b but are now moving to a multinational phase 2
That progress and commitment should be reassuring.
This is one of the better PRs this year. We are halfway through the year. Leo……IBD and B in capsules! Let’s go!
WAKEFIELD, MA – May 13, 2021 (GLOBE NEWSWIRE) Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today announces the filing of its SEC Form 10-Q (quarterly report), for the quarter ended March 31, 2021. During the quarter, the Company made substantive progress in the development of Brilacidin, Innovation Pharma’s flagship drug candidate in a new class of compounds called defensin-mimetics.
Of particular note, in January, the U.S. Food and Drug Administration (FDA) designated the investigation of Brilacidin for the treatment for COVID-19 as a Fast Track development program.
In February, recruitment began for the Company’s international Phase 2, ~120-patient, randomized, double-blind, placebo-controlled clinical trial evaluating Brilacidin for treatment of moderate-to-severe COVID-19 in hospitalized patients (see NCT04784897). Early in April, enrollment in the trial reached 25 percent. Upon review of safety data, per protocol, the independent Data Monitoring Committee (DMC) recommended increasing the dosing regimen of Brilacidin from 3 days to 5 days of treatment, which has been implemented and may further maximize Brilacidin’s therapeutic benefits. At the end of April, enrollment in the COVID-19 trial reached 50 percent, and as of today, the Company is pleased to report enrollment now exceeds 70 percent.
Since the COVID-19 outbreak, Brilacidin has garnered attention due to its unique 3-in-1 therapeutic potential—antiviral, anti-inflammatory, antimicrobial—to treat COVID-19 and associated complications. Extensive antiviral research conducted to date resulted in publication of findings related to Brilacidin’s anti-SARS-CoV-2 activity in Viruses, a peer-reviewed journal, with Brilacidin also selected for academic presentations, leading to added exposure for the Company. Further, an independent Machine Learning/Artificial Intelligence model used to screen 1,482 compounds ranked Brilacidin in the top three percent of compounds predicted to be the most effective against SARS-CoV-2, the virus responsible for COVID-19. The Company is encouraged by the Brilacidin antiviral data generated thus far, as it is supportive of Brilacidin’s potential to become a front-line antiviral treatment for COVID-19.
Also in the pipeline, Alfasigma S.p.A. (“Alfasigma”)—the licensee of worldwide rights to develop, manufacture and commercialize rectally-administered Brilacidin for treatment of Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS)—notified the Company, in April, of its intentions to commence, in 2021, a Phase 2 multinational clinical trial of Brilacidin for UP/UPS. Alfasigma has placed an order with the Company for Brilacidin drug substance needed for the trial, which the Company is in the process of supplying. Per the licensing agreement, Innovation Pharma is eligible to receive $24 million in upfront and milestone payments, and a 6 percent royalty (net sales), upon the successful marketing of Brilacidin for UP/UPS.
“It was a busy and productive quarter for us,” said Leo Ehrlich, Chief Executive Officer at Innovation Pharmaceuticals. “Patient enrollment in the Phase 2 study of Brilacidin for COVID-19 is moving along quickly, far faster in recruitment than other COVID-19 studies we’ve seen in industry reports. We are optimistic about Brilacidin’s COVID-19 treatment prospects, and are further encouraged by the broad spectrum antiviral properties Brilacidin is exhibiting based on ongoing lab research in multiple viruses.”
Ehrlich continued: “Elsewhere, it was exciting to learn that Alfasigma is planning to commence a Phase 2 trial of Brilacidin for treatment of UP/UPS this year, which complements our goal to develop oral Brilacidin in Inflammatory Bowel Diseases. That Alfasigma is investing substantial resources and monies in the clinical development of Brilacidin is a reassuring sign they continue to see therapeutic promise and commercial merit in Brilacidin in the area of IBD, as do we. Development work related to the formulation and manufacture of Brilacidin in capsule form is underway to support our Phase 2 trial in Ulcerative Colitis planned to commence this year. Additional work tied to starting, in 2022, a planned Phase 3 study of Brilacidin in Oral Mucositis is also in progress. We aim to maintain momentum across our clinical programs.”
The shadows that have been casted here for years are about to give way to bountiful sunshine. Leo has our best interest and has fought hard.
I agree. This is so much more than Covid. Covid is the platform and a great opportunity in itself, but the antiviral possibilities and new patents that will arise with many reformulation hopes are endless in a 44 billion market by 2026.
Let’s hope for good data and more data
Delta is expected to bring a surge in Sept
Let’s hope we get great data in August.
https://www.cnn.com/2021/06/22/health/covid-variant-delta-gamma/index.html
So does adderrall
AstraZeneca PLC said Tuesday that a Phase 3 trial to assess the safety and efficacy of a long-acting antibody combination, called AZD7442, for the prevention of symptomatic Covid-19 after exposure didn't meet the primary goal.
I’ll take 200 million in first year. Lol
Have not seen any YET! More drought in the Midwest. Is all I see
I’m not sure Alan. The game is one sided. Leo needs to close a deal to make them pay.
Good post.
$44 Billion Antiviral market by 2026
This is not only about C19...it’s about so much more and unlocking the door to extreme success.
Enrollment complete. IMO the trial started to move quickly at the end and imo that is a great sign. Congrats
Where are millions of shares? U just accumulating?
Largest short on record. No new shares last quarter. News and trial results on the way.
If all is well and data is stellar and we get eau....and in other countries where drugs are needed......it simply helps the Brilacidin story and other indications should have an easier more rapid road ahead
If that was the case I’d expect $5 overnight for starters. Then a climb to teens and 20’s after people realize the potential and indications.
If results are very good I’d expect dollar land very quickly. The world needs antivirals and especially for Covid.
OM is still my favorite for quick money.
IBD is my next.
Clock is ticking
Full enrollment to be announced - next
50% complete end of April. 75% complete mid May....I’d expect completion this upcoming week or next.
Things will start heating up here as we await topline. Imagine getting into a stock at .20 that has a chance to show great phase 2 results including the stellar safety profile.
Fingers crossed this is finally IPIX time to shine as Covid tears apart India and other countries. Truly sad it has taken this long to get B here while people are dying. (If it proves to be a winner)
Yup no new shares OS. And we increased our cash position by 5 million. People have said that trials are paid upfront to an extent. So I’m hoping we continue with an over 10million cash position to start Oral UC. If this viral trial is good we may have a partner prior.
I’d like to see over a dollar by August.
No new shares into market. Added 5 million in cash$$$. 8 to 13 million.
I’d say that is a first in years. No new shares printed.
Great point. No new shares this Q.
For all the investors who like to buy ahead of trial completion. Your timing has just moved up. Late June to early May.
Recruitment will be complete in may. Mark this post. Moving at speed of light